

AD _____

GRANT NUMBER DAMD17-94-J-4458

TITLE: Characterization of Novel Seven Transmembrane Helix,
GS-Coupled Receptors and Pou Domain Proteins in Cancer
of the Mammary Epithelium

PRINCIPAL INVESTIGATOR: Michael G. Rosenfeld, M.D.

CONTRACTING ORGANIZATION: University of California, San Diego
La Jolla, California 92093-0934

REPORT DATE: September 1997

TYPE OF REPORT: Annual

PREPARED FOR: Commander
U.S. Army Medical Research and Materiel Command
Fort Detrick, Frederick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY (Leave blank) 2. REPORT DATE
September 1997 3. REPORT TYPE AND DATES COVERED
Annual (1 Sep 96 - 31 Aug 97)

4. TITLE AND SUBTITLE
Characterization of Novel Seven Transmembrane Helix, GS-Coupled Receptors and Pou Domain Proteins in Cancer of the Mammary Epithelium

5. FUNDING NUMBERS
DAMD17-94-J-4458

6. AUTHOR(S)
Michael G. Rosenfeld, M.D.

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)
University of California, San Diego
La Jolla, California 92093-0934

8. PERFORMING ORGANIZATION REPORT NUMBER

9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES)
Commander
U.S. Army Medical Research and Materiel Command
Fort Detrick, Frederick, Maryland 21702-5012

10. SPONSORING/MONITORING AGENCY REPORT NUMBER

11. SUPPLEMENTARY NOTES

12a. DISTRIBUTION / AVAILABILITY STATEMENT
Approved for public release; distribution unlimited

12b. DISTRIBUTION CODE

13. ABSTRACT (Maximum 200)

Understanding the molecular basis of breast carcinoma is central to designing rational and effective therapy for this prevalent disease. We have proposed to investigate several regulatory proteins that we hypothesized may underlie at least a subset of human breast carcinomas. In investigating transcription factors of the POU domain class and their synergistic interactions with nuclear receptors, we have discovered a novel protein, expressed in the breast, that acts as a specific repressor of retinoic acid and thyroid hormone receptors. This 270kDa protein, postulated to mediate retinoic acid and thyroid hormone receptor actions as a repressor of specific gene expression, is recruited to estrogen receptor by antagonists and its regulation appears to underlie resistance in ER positive tumors..

4. SUBJECT TERMS
Breast Cancer

15. NUMBER OF PAGES
21

16. PRICE CODE

7. SECURITY CLASSIFICATION OF REPORT
Unclassified

18. SECURITY CLASSIFICATION OF THIS PAGE
Unclassified

19. SECURITY CLASSIFICATION OF ABSTRACT
Unclassified

20. LIMITATION OF ABSTRACT
Unlimited

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

___ Where copyrighted material is quoted, permission has been obtained to use such material.

___ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

___ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

MJR In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

MJR For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

MJR In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

MJR In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

___ In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

Michael G. Bradford

PI - Signature

8/28/97

Date

4. TABLE OF CONTENTS

		Page
1.	Front Cover	1
2.	SF298- Report Document Page	2
3.	Foreword	3
4.	Table of Contents	4
5.	Introduction	5
6.	Body	7
7.	Conclusions	9
8.	References	12
9.	Appendix	20
	Figure Legends (1)	20
	Figures (1)	21

5. SUMMARY OF PROGRESS

Breast cancer is a devastating disease, the etiology of which may be best understood by investigating the regulatory events that can maintain or restore normal growth properties. Our laboratory has investigated control of gene transcription and mammalian development, emphasizing two classes of transcription factors: POU domain factors, and nuclear receptors that mediate both positive and negative patterns of gene expression. Our ongoing studies under this Award are based on the premise that these factors, and trophic receptors under their control, are of specific significance to the etiology and treatment of breast cancer.

We have perused our original goals emphasized transcription factors of the POU domain class and their synergistic interactions with nuclear receptors, and a novel seven-transmembrane helix receptor expressed in breast. Our most important findings have been the discovery of coregulators of estrogen receptors, including novel nuclear receptor co-repressor protein, referred to as N-CoR. We have continued to emphasize the role of this factor in breast cancer, because it has important implications for the large number of women who have estrogen receptor positive tumors. A major therapeutic problem is the occurrence of resistance to the most widely used estrogen antagonist, tamoxifen or 4-hydroxy tamoxifen. Over the past year we have reached initial understanding of the mechanism of tamoxifen action which works as a repressor in normal breast and in breast tumors, and the molecular basis of the development of tamoxifen resistance. Thus nuclear receptor co-repressor (N-CoR) can bind to the estrogen receptor in the presence of the antagonist (partial agonist) tamoxifen, and while, in turn is dominant to the actions of, activating co-factors that associate with the receptor N-terminus. We believe that these studies will ultimately permit categorization of tamoxifen resistance and new approaches to therapy. The Army Breast Cancer Grant provides the only source of funding for this research, and we believe that we are in a position to provide important contributions to treatment of estrogen receptor positive tumors under the support of this grant.

While we will continue to complete our study of Specific POU domain novel seven transmembrane helix gene expressed in breast, our emphasis will clearly be focused on the estrogen receptor project, because it represents the most important project on which to focus our continued resources under this grant, we believe that, in this way, we will provide the maximum benefit to the area of breast cancer research.

INTRODUCTION

The morphogen retinoic acid is required for development, growth and differentiation (reviewed in 1 and 2). Retinoids, a group of analogs of vitamin A, particularly at high levels, suppress carcinogenesis in various epithelial tissues, including the mammary gland (3-6). We believe that this reflects the actions with a co-repressor that we believe may serve roles in initiation of breast cancer. The hormone effects are mediated by binding to specific nuclear receptors (3) that are members of the steroid/thyroid hormone receptor super family (4-6). This class of proteins functions as ligand dependent transcription factors that mediate the response of the hormone signal by direct control of gene expression. The estrogen and glucocorticoid receptors bind DNA as homodimers, while retinoic acid receptors preferably interact with their cognate DNA response elements as components of heterodimeric complexes (7-20) often involving a partner that our laboratory and others identified to be members of the retinoid X receptor (RXR) family (8-21). Heterodimers of retinoic acid receptor and retinoid X receptor bind with high affinity and activate transcription from response elements consisting of direct repeats, palindrome or inverted palindromic arrangements of a core recognition motif (4, 8-21). The relative orientation and spacing of the core recognition motifs play essential roles in the specificity of the DNA binding and transcriptional activation. While heterodimers of retinoic acid

receptor and retinoid X receptor bind to direct repeats of core motifs spaced by 1, 2 and 5 bp (DR+1, DR+2, and DR+5), an unspaced palindrome binds to an inverted palindromic arrangement of the core motif spaced by 6-8 bp, (e.g. IP+6) reviewed in 22,23).

Recent studies indicate that heterodimeric complexes of retinoic acid receptor and retinoid X receptor molecules exhibit a polarity binding to various DNA elements (24-26), and that this polarity-specific binding may play important roles in cell-specific regulation by retinoic acid receptors. On a direct repeat spaced by 5 bp (DR+5) retinoid X receptor selectively binds to the upstream half-site and retinoic acid receptor binds to the downstream half-site (25,26). When the spacing is reduced by one basepair (DR+4 site) the element becomes a binding site for heterodimers of thyroid hormone receptor and retinoid X receptor. In this case the thyroid hormone receptor is bound to the downstream half-site and the retinoid XD receptor again interacts with the upstream half-site. However, in the case of a direct repeat spaced by 1 bp (DR+1), retinoid X binds on the 3' site (27). The stringency of this polarity-specific binding was further confirmed using specific mutants of retinoid X receptor containing the P-box residues of the glucocorticoid receptor (27). In contrast to the glucocorticoid receptor, retinoic acid receptors are not associated with heat shock proteins in the absence of hormone, but are bound to their response elements and are able to actively repress basic transcription (28,29).

The cellular thyroid hormone receptor, like the viral oncogene *erbA* of the Avian Erythroblastosis Virus (AEV), *V-erbA*, represses transcription of target genes in the absence of ligand, with hormone binding resulting in de-repression and activation (31,34,35,45). Evidence has indicated that in most cases ligand-independent repression appears to result from an active repressor function within the ligand binding domain. A ligand-independent repression function could be transferred by the carboxyl-terminal region of the thyroid hormone receptor to heterologous DNA binding domain. Fusion of the C-terminal domains of *v-erbA*, *T₃R*, and *RAR* to the DNA binding domain of the yeast transcription factor *GAL4*, generated *UAS*-dependent transcriptional repressor proteins (31). In contrast, the *RXR* C-terminus fused to the *GAL4* DNA binding domain did not mediate transcriptional silencing. Our laboratory and others, were able to show that this repression was mediated by the C-termini of the retinoic acid and thyroid hormone receptors (30-33), thus, thyroid hormone and with the polarity of binding on sites with asymmetric core motifs (17, 36-44), dictate whether the receptor exerts either positive control of gene transcription .

The molecular mechanisms responsible for nuclear receptor transcriptional silencing have not been well understood until the past year. Recent studies showed that several nuclear receptors may interact with the basal transcription factors, including *TFII β* (47); however, the distal *T₃* receptor thyroid hormone C-terminal regions interact with *TFII β* , are not sufficient to confer repression. Indeed, the regions in the hinge and N-terminal part of the ligand-binding domain of the thyroid hormone receptor are required for silencing (46,47). Co-transfection experiments suggest that these sequences which do not bind *TFII β* can potentially compete for a putative soluble co-repressor molecule (47) and imply that existence of additional interaction factors required for ligand-independent repression. Last year, under this Grant, we isolated and characterized a novel 270 kDa factor (*N-CoR*) characterized by an interaction domain in the distal C-terminus, and a receptor in the mutant cell and also interacts with retinoic acid receptor, but not with the unliganded estrogen, progesterone, retinoid X, glucocorticoid, or vitamin D receptors. Receptor specific mutations in this region that abolished interactions with the 270 kDa protein also eliminated the ligand-independent repression function of the thyroid hormone receptor, retinoic acid, and because 270 kDa protein can itself function as a repressor, our data suggested that the 270 kDa protein associated with the unliganded, DNA-bound thyroid hormone receptor, and retinoic acid is required for ligand-independent transcriptional repression; we, therefore, termed this protein *N-CoR* for nuclear receptor co-repressor (51-53).

Several lines of evidence indicate that nuclear receptors must interact with additional factors dependent on a conserved distal C-terminal motif (AF2) to mediate both activation and repression of gene expression (48-52). Biochemical assays have identified 140 and 160 kDa proteins (p140 and p160) (49,48,52) that associate with estrogen, retinoic acid, thyroid hormone, retinoid X, and potentially other nuclear receptors as the most prominent ligand-dependent putative co-activators, binding in an AF2-dependent fashion. In addition, a series of proteins exhibiting ligand-dependent interactions with the C-termini of nuclear receptors that may also function as co-activators have been identified using a yeast two-hybrid screen.

6. BODY

Over the past two years, we have worked to identify the p160 exhibiting ligand-dependent association with DNA-bound thyroid hormone and retinoic acid receptors in the presence of thyroid hormone and to understand how the molecules function. The ligand-binding domains of estrogen receptor and other nuclear receptors, including retinoic acid and thyroid hormone receptors, interact strongly in the cell with a conserved domain in the N-terminus of CBP and p300 in a ligand-dependent manner. Further, the putative co-activator p160 was found to interact independently and specifically with a conserved C-terminal domain in CRIB binding protein CBP and p300. Expression cloning of a family of p160 cDNAs was achieved based on estrogen receptor and CBP interaction. Several independent experimental approaches have suggested a central role of CBP in ligand-dependent activation of RAR and T3R. One of the p160 factors (NCoA-1) appears to be associated directly with liganded estrogen receptors, while a second (p/CIP) is primarily associated with CBP; yet both are required for estrogen-dependent activation. In addition, the CBP-associated factor harboring intrinsic histone acetylase function p/CAF, is required for nuclear receptor function..

Our data revealed that, in a concentration-dependent fashion, anti-CBP IgG specifically inhibited ligand-dependent activation of transcription units containing retinoic acid response elements, without altering expression of other promoters. (57)

Because CBP and/or its related family members were required for transactivation by retinoic acid and other nuclear receptors, we investigated the possibility that putative nuclear receptor co-activators, p140 or p160, could themselves interact with CBP. A region of 105 amino acids that was sufficient for interactions with p160. In addition, ³²P-CBP C-terminus could detect p160 in Far-Western experiments. These cDNAs encoding the putative p160 (nuclear receptor co-activator, NCoA) were obtained by expression cloning based on the criteria that phage plaques exhibit interaction with both CBP C-terminus and liganded nuclear receptors and gene products were identified and full copy cDNA obtained (Figure 3). The first (NCoA-1) encoded a variant forms of the SRC-1 protein, initially reported to have a predicted molecular weight of 115 kDa (54). N-terminally extended variants included forms containing 1465 and 1402 amino acids, with predicted molecular weights of 159 and 152 kDa respectively. We also identified two additional family members (referred to as NCoA-2, and p/CIP). P/CIP proves to be very largely expressed in breast tumor cells. Based on immunodepletion experiments, these p160 factors are the biochemically-identified p160. Microinjection assays confirmed that both NCoA-1 and p/CIP are required for estrogen and retinoic acid receptor-dependent activation events.(55) Nuclear receptors, CBP, NCoA and p/CIP interact with conserved leucine charged residue rich domains (LCD) motifs, apparently amphipathic helices (i.e. hydrophobic on one gene, hydrophilic in the other gene) that are present in all factors known to be recruited to the corepressor complex (57).

N-CoR AND SMRT ARE PART OF A CO-REPRESSOR COMPLEX:

Consistent with a role of N-CoR in mediating the biological effects of estrogen antagonists, decreased N-CoR levels are found to correlate with the acquisition of tamoxifen resistance by human breast cancer cell in nude mouse model.

Recently, N-CoR and SMRT have been found to be components of corepressor complexes (56,58,59) that also include the distinct histone deacetylases HDAC1 (60) and HDAC2/mRPD3 (61), as well as the corepressor mSin3 (62,63). Recent work by our laboratory and others has shown that HDAC2 is recruited to DNA via targeting by diverse site-specific transcription factors (56,58,59,64-71). This led to the hypothesis that histone deacetylation results in a structural rearrangement of chromatin and, by an as yet poorly understood mechanism, transcriptional repression. This model provides a conceptual link between external stimuli, recruitment of corepressor complexes, and resulting alterations of chromatin that modulate gene transcription.

Recently, N-CoR was independently identified as a progesterone receptor-binding protein in the obligatory presence of the antiprogestin RU486 (70). Our results suggest that receptors other than the thyroid hormone and retinoic acid receptors may, under some conditions, recruit the N-CoR corepressor complex. Conversely transcriptional activation by nuclear hormone receptors, requires the histone acetylases CBP/p300 (73-73) and p/CAF (61). Thus, the ligand-mediated switch of a nuclear receptor from transcriptional repression to transcriptional activation reflects an exchange of a histone deacetylase-containing corepressor complex for a coactivation complex containing multiple histone acetylase functions (56).

This issue is clinically relevant because the development of inhibitory ligands for the nuclear receptors, that seemingly do not cause the switch in complexes, has yielded important therapeutic treatments, among them the use of tamoxifen for endocrine therapy of breast cancer. The tamoxifen-related compounds, including trans-hydroxytamoxifen (TOT) are thought to inhibit estradiol-dependent transactivation by competitive binding to the estrogen receptor (74,75). However, in certain tissues such as uterus and bone, and after long term treatment in patients with breast cancer, tamoxifen exhibits partial agonistic activity thought to be mediated by the constitutively active AF-1 domain of the estrogen receptor, although the mechanism by which tamoxifen exerts differential effects in various tissues has remained elusive (76). Substances which raise intracellular cAMP levels or stimulate the ras/MAP kinase pathway can also cause the estrogen receptor to activate in the absence of its activating ligand (77-83).

Over the past year, we have demonstrated that diverse strategies are used by the breast all in regulating the association of specific N-CoR or SMRT-containing complexes with nuclear receptors, which includes in addition to the DNA site, the nature of the ligand, the levels of N-CoR/SMRT, and the action of several protein kinase-dependent signaling cascades. These diverse regulatory events alter the association of the receptor with corepressors and coactivators, and coordinately dictate whether these nuclear receptors will repress or activate the transcription of target genes.

The regulation of the corepressor binding appears to be biologically important for diverse functions; for example, retinoic acid receptors prove to be constitutively active in the absence of N-CoR, and the absence of either N-CoR or SMRT converts steroid receptor antagonists to functional agonists by allowing the receptor N-terminus to recruit the identical CBP/ p/CIP complex required for activation by the liganded estrogen receptor C-terminus. These regulatory events dictate the nature of the ligand response in normal and tumor cell types, and present several new approaches to problems of resistance in antagonists-treated, receptor positive breast cancers.

7. CONCLUSIONS

Modulation of the association of receptors with corepressor complex

Recent evidence has suggested that nuclear receptor function is dependent upon the recruitment of specific coactivator and corepressor complexes. In this manuscript, we present evidence that regulation of the corepressor complex is critical for normal homeostasis and that it actually serves to impose ligand-dependence on those nuclear receptors that bind N-CoR constitutively. Thus, when the binding of N-CoR to the unliganded retinoic acid receptor is prevented, the receptor becomes capable of functioning as a constitutive activator. An antiprogesterin and the Class I antiestrogens (tamoxifen-like) induce recruitment of the N-CoR corepressor complex to receptors that, unlike thyroid hormone and retinoic acid receptors, do not bind effectively to corepressors in the unliganded state (51). Even pure antagonists (e.g. LG 629) of the retinoic acid receptor fail to entirely inhibit activation in the absence of N-CoR binding. Similarly, blocking receptor association with N-CoR converts the anti-estrogen TOT into an agonist, suggesting that either a decreasing level of N-CoR, or inhibition of corepressor binding to the receptor, might account for the ability of TOT to induce activation in specific cell types and we provide evidence that both types of regulation do occur. Therefore, a critical biological role of the N-CoR corepressor complex is to suppress constitutive activation and thus impart ligand dependence on the many developmental and homeostatic events controlled by specific nuclear receptors.

Our studies, in concert with reports that overexpression of N-CoR/SMRT opposes the effects of coactivators (SRC-1/NCoA-1 in particular) that allowed antagonistic ligands to act as partial agonists, indicate that the cell type-specific activation effects of tamoxifen derivatives are mediated by the receptor N-terminal (AF-1) domain and are normally blocked by the association of N-CoR with the receptor C-terminus. Thus activation function of the N-terminus appears itself to be dependent upon SRC-1/NCoA-1 and the p/CIP/CBP complex. While there are weak *in vitro* interactions between the estrogen receptor N-terminus and p/CIP, as well as SRC-1/NCoA-1, it is likely that these coactivators participate in either cooperative interactions with the receptor C-terminus and/or that an additional N-terminus associated bridging factor(s) stabilizes the binding of the coactivator complex. Indeed, stimulation of cAMP-dependent and MAPK signaling pathways in cells appears to increase the interactions between the nuclear receptor AF-1 domain and components of the p/CIP/CBP complex, in parallel to facilitating the dismissal of N-CoR from the receptor AF-2 domain. We hypothesize that N-CoR or SMRT complexes on the antagonist-bound receptor C-terminus weakly interact with the constitutive receptor N-terminus and influence the association of coactivators. We propose that, two independent activation domains in the same receptor recruit the identical coactivator complex, or a complex containing at least a subset of the factors required in ligand-induced response, and this accounts for the instances of reported synergy between those domains (84,85).

These observations support the proposal that the nature of the transcriptional response to ligand depends on the highly regulated ability of nuclear receptors to accurately shift between a coactivator complex with histone acetylase activity and a corepressor complex containing histone deacetylase activity and provides a model system for other classes of transcription factors.

Regulation of corepressor complexes *in vivo*

The biochemical data presented in this manuscript predict that any decrease in levels of N-CoR or in the affinity of the receptor for the corepressor could cause a shift in tamoxifen from antagonist to agonist, with clear implication in regard to certain pathological conditions and the use of receptor antagonists in treatment of cancers. Indeed, in mouse models of tamoxifen resistance, we observe a statistically significant correlation between decreased levels of N-CoR and

the transition of MCF7-derived tumors from tamoxifen-sensitivity to tamoxifen-resistance. Additionally, many breast tumors eventually develop high levels of tyrosine kinase receptors or of intracellular cAMP (86,87) which, according to our data, would be predicted to favor the conversion of tamoxifen to agonist function by causing release of the corepressor complex. In contrast, as HepG2 cells seem to contain a normal complement of N-CoR alone, we speculate that a signaling pathway which decreases recruitment of the N-CoR component is misregulated in these cells, causing failure of TOT to act as an antagonist in the cell line. As stimulation of protein kinase A and MAP kinase pathways in the presence of estradiol results in synergistic activation of estrogen receptor in cell-type specific manner (88), these pathways could also act to amplify the agonist activity of tamoxifen even at normal levels of N-CoR, promoting tumor growth. A switch in preference for binding the coactivator or corepressor complexes provides a mechanism by which signal transduction events initiated at the cell membrane can influence diverse nuclear receptors.

PLANS FOR NEXT YEAR

As outlined in our Plans for last year's Progress report, this year we plan:

- Task I To continue to generate and analyze animals null for the BrR receptor factor genomic loci.
- Task II (Continuation from Year 2 Progress Report) Further investigate the regulation of the nuclear receptor co-repressor, N-CoR, in breast tumors.
- Task III (Continuation from Year 1 Progress Report) To further study the recently identified p/CIP and the role of its gene amplification in breast cancer.
- Task IV (Initiated from Year 2) To further link the co-repressor and co-activator to drug-resistant breast cancer. We will further investigate the model that inhibitors (tamoxifen) used in clinical breast cancer causing estrogen receptor to bind the nuclear receptor co-receptor, and are controlled both by regulation of levels of NCoR and by specific signal transduction pathways, in clinical cases of tamoxifen resistance.

8. REFERENCES

1. Schwartz, H.L. (1983). Molecular Basis Of Thyroid Hormone Action. Academic Press pp. 413-444.
2. Ragsdale, C.W. and Brockes, J.P. (1991). Nuclear Hormone Receptors. Academic Press pp. 235-259.
3. Bigler, J. and Eisenmann, R.N. (1988). C-erbA encodes multiple proteins in chicken erythroid cells. *Mol. Cell Biol.* **8**: 4155-4161.
4. Evans, R.M. (1988). The steroid and thyroid hormone receptor superfamily. *Science* **240**: 889-895.
5. Green, S. and Chambon, P. (1988). Nuclear receptors enhance our understanding of transcription regulation. *Trends Genet.* **4**: 309-314.
6. Beato, M. (1989). Gene regulation by steroid hormones. *Cell* **56**: 335-344.
7. Glass, C.K., Lipkin, S.M., Devary, O.V., and Rosenfeld, M.G. (1989). Positive and negative regulation of gene transcription by a retinoic acid-thyroid hormone receptor heterodimer. *Cell* **59**: 697-708.
8. Forman, B.M., Yang, C.R., Au, M., Casanova, J., Ghysadael, J., and Samuels, H.H. (1989). A domain containing leucine-zipper-like motifs mediate novel *in vivo* interactions between the thyroid hormone and retinoic acid receptors. *Mol. Endo.* **3**: 1610-1626.
9. Murray, M.B. and Towle, H.C. (1989). Identification of nuclear factors that enhance binding of the thyroid hormone receptor to a thyroid hormone response element. *Mol. Endo.* **3**: 1434-1442.
10. Burnside, J., Darling, D.S., and Chin, W.W. (1990). A nuclear factor that enhances binding of thyroid hormone receptors to thyroid hormone response elements. *J. Biol. Chem.* **265**: 2500-2504.
11. Rosen, E.D., O'Donnell, A.L., and Koenig, R.J. (1992). Ligand-dependent synergy of thyroid hormone and retinoid X receptors. *J. Biol. Chem.* **267**: 22010-22013.
12. Kliewer, S.A., Umesono, K., Noonan, D.J., Heyman, R.A., and Evans, R.M., (1992). Convergence of 9-cis retinoic acid and peroxisome proliferator signaling pathways through heterodimer formation of their receptors. *Nature* **358**: 771-774.
13. Leid, M., Kastner, P., and Chambon, P., (1992). Multiplicity generates diversity in the retinoic acid signaling pathways. *Trends Biochem. Sci.* **17**: 427-433.
14. Marks, M.S., Hallenbeck, P.L., Nagata, T., Segars, J.H., Appella, E., Nikodem, V.M., and Ozato, K., (1992). H-2RIIBP (RXR beta) heterodimerization provides a mechanism for combinatorial diversity in the regulation of retinoic acid and thyroid hormone responsive genes. *EMBO J.* **11**: 1419-1435.

15. Zhang, X.K., Lehmann, J., Hoffmann, B., Dawson, M.I., Cameron, J., Graupner, G., Hermann, T., Tran, P., and Pfahl, M. (1992). Homodimer formation of retinoid X receptor induced by 9-cis retinoic acid. *Nature* 358: 587-591.
16. Mangelsdorf, D.J., Umesono, K., Kliewer, S.A., Borgmeyer, U., Ong, E.S., and Evans, R.M. (1991). A direct repeat in the cellular retinol-binding protein type II gene confers differential regulation by RXR and RAR. *Cell* 66: 555-561.
17. Umesono, K., Murakami, K.K., Thompson, C.C., and Evans, R.M. (1991). Direct repeats as selective response elements for the thyroid hormone, retinoic acid, and vitamin D3 receptors. *Cell* 65: 1255-1266.
18. Näär, A.M., Boutin, J.M., Lipkin, S.M., Yu, V.C., Holloway, J.M., Glass, C.K., and Rosenfeld, M.G. (1991). The orientation and spacing of core DNA-binding motifs dictate selective transcriptional responses to three nuclear receptors. *Cell* 65: 1267-1279.
19. Katz, R.W. and Koenig, R.J. (1993). Nonbiased identification of DNA sequences that bind thyroid hormone receptor alpha 1 with high affinity. *J. Biol. Chem.* 268: 19392-19397.
20. Luisi, B.F., Xu, W.X., Otwinowski, Z., Yamamoto, K.R., and Sigler, P.B., (1991). Crystallographic analysis of the interaction of the glucocorticoid receptor with DNA. *Nature* 352: 497-505.
21. Umesono, K., Giguere, V., Glass, C.K., Rosenfeld, M.G., and Evans, R.M. (1988). Retinoic acid and thyroid hormone induce gene expression through a common responsive element. *Nature* 336: 262-265.
22. Yu, V.C., A.M. Näär, and M.G. Rosenfeld. (1992). Transcriptional regulation by the nuclear receptor superfamily. *Current Opinion in Biotechnology* 3: 596-601.
23. Glass, C.K. Differential recognition of target genes by nuclear receptor monomers, dimers, and heterodimers. *Endocrine Reviews* 15: 391-407.
24. Yen, P.M., Ikeda, M., Brubaker, J.H., Forgione, M., Sugawara, A., and Chin, W.W. (1994). Roles of v-erbA homodimers and heterodimers in mediating dominant negative activity by v-erbA. *J. Biol. Chem.* 269: 903-909.

25. Kurokawa, R., Yu, V.C., Näär, A., Kyakumoto, S., Han, Z., Silverman, S., Rosenfeld, M.G., and Glass C.K. (1993). Differential orientations of the DNA-binding domain and carboxy-terminal dimerization interface regulate binding site selection by nuclear receptor heterodimers. *Genes & Dev.* 7: 1423-1435.
26. Predke, P.F., Zamble, D., Sarkar, B., and Giguere, V. (1994). Ordered binding of retinoic acid and retinoid-X receptors to asymmetric response elements involves determinants adjacent to the DNA-binding domain. *Mol. Endo.* 8: 31-39.
27. Kurokawa, R., DiRenzo, J., Boehm, M.F., Sugarman, J., Glass, B., Rosenfeld, M.G., Heyman, R.A., and Glass, C.K. (1994). Regulation of retinoid signaling by receptor polarity and allosteric control of ligand binding. *Nature* 371: 528-531.
28. Levine, M. and Manley, J.L. (1989). Transcriptional repression of eukaryotic promoters. *Cell* 59: 405-408.
29. Renkawitz, R. (1990). Transcriptional repression in eukaryotes. *Trends Genet.* 6: 192-197.
30. Holloway, J., Glass, C.K., Adler, S., Nelson, C.A., and Rosenfeld, M.G., (1990). The C'-terminal interaction domain of the thyroid hormone receptor-dependent repression of transactivation by the vitamin D, thyroid hormone and retinoic acid receptors. *J. Biol. Chem.* 268: 4152-4154.
31. Baniahmad, A., Tsai, S.Y., O'Malley, B.W., and Tsai, M.J. (1992). Kindred S thyroid hormone receptor is an active and constitutive silencer and a repressor for thyroid hormone and retinoic acid responses. *Proc. Natl. Acad. Sci. USA* 89: 10633-10637.
32. Fondell, J.D., Roy, A.L., and Roeder, R.G., (1993). Unliganded thyroid hormone receptor inhibits formation of a fusion factor-dependent repression of transactivation by the vitamin D, thyroid hormone, and retinoic acid receptors. *J. Biol. Chem.* 268: 4152-4160.
33. Chambon, P. (1995). The molecular and genetic dissection of the retinoid signaling pathway. *Recent. Prog. Horm. Res.* 50: 317-332.
34. Sap, J., Muñoz, A., Schmitt, J., Stunnenberg, H., and Vennstrom, B., (1989). Repression of transcription mediated at a thyroid hormone response element by the v-erb-A oncogene product. *Nature* 340: 242-244.
35. Damm, K., Thompson, C.C., and Evans, R.M. (1989). Protein encoded by v-erb-A functions as a thyroid-hormone antagonist. *Nature* 339: 593-597.

36. Yu, V.C., Delsert, C., Andersen, B., Holloway, J.M., Devary, O.V., Näär, A.M., Kim, S.Y., Boutin, J.M., Glass, C.K., and Rosenfeld, M.G. (1991). RXR beta: a coregulator that enhances binding of retinoic acid, thyroid hormone and vitamin D receptors to their cognate response elements. *Cell* 67: 1251-1266.
37. Kliewer, S.A., Umesono, K., Mangelsdorf, D.J. and Evans, R.M. (1992). Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signaling. *Nature* 355: 446-449.
38. Leid, M., Kastner, P., Lyons, R., Nakshatri, H., Saunders, M., Zacharewski, T., Chen, J.Y., Staub, A., Garnier, J.M., Mader, S., and Chambon, P. (1992). Purification, cloning, and RXR identity of the HeLa cell factor with which RAR or TR heterodimerizes to bind target sequences efficiently. *Cell* 68: 377-395.
39. Marks, M.S., Hallenbeck, P.L., Nagata, T., Segars, J.H., Appella, E., Nikodem, V.M., and Ozato, K. (1992). H-2RIIBP (RXR beta) heterodimerization provides a mechanism for combinatorial diversity in the regulation of retinoic acid and thyroid hormone responsive genes. *EMBO J.* 11: 1419-1435.
40. Zhang, X.-K., Hoffman, B., Tran, P.B.-V., Graupner, G., and Pfahl, M. (1992). Retinoid X receptor is an auxiliary protein for thyroid hormone and retinoic acid receptors. *Nature* 355: 441-446.
41. Kurokawa, R., Yu, V., Näär, A., Kyakumoto, S., Han, Z., Silverman, S., Rosenfeld, M.G., and Glass, C.K. (1993). Differential orientations of the DNA binding domain and C-terminal dimerization interface regulate binding site selection by nuclear receptor heterodimers. *Genes & Dev.* 7: 1423-1435.
42. Perlmann, T., Rangarajan, P.N., Umesono, K., and Evans, R.M. (1993). Determinants for selective RAR and TR recognition of direct repeat HREs. *Genes & Dev.* 7: 1411-1422.
43. Näär, A.M., Boutin, J.M., Lipkin, S.M., Yu, V.C., Holloway, J.M., Glass, C.K., and Rosenfeld, M.G. (1991). The orientation and spacing of core DNA-binding motifs dictate selective transcriptional responses to three nuclear receptors. *Cell* 65: 1267-1279.
44. Glass, C.K., Devary, O.V., and Rosenfeld, M.G. (1990). Multiple cell type-specific proteins differentially regulate target sequence recognition by the alpha retinoic acid receptor. *Cell* 63: 729-738.
45. Muñoz, A., Zenke, M., Ulrich, Gehring, Sap, J., Beug, H., and Vennström, B. (1988). Characterization of the hormone-binding domain of the chicken c-erbA/thyroid hormone receptor protein. *EMBO J.* 7: 155-159.

46. Baniahmad, A., Ha, I., Reinberg, D., Tsai, S., Tsai, M.-J., and O'Malley, B.W. (1993). Interaction of human thyroid hormone receptor beta with transcription factor TFIIB may mediate target gene depression and activation by thyroid hormones. *Proc. Natl. Acad. Sci. USA* 90: 8832-8836.
47. Baniahmad, A., Lendg, X., Burris, T.P., Tsai, S.Y., Tsai, M. and O'Malley, B.W. (1995). The TAU4 activation domain of the thyroid hormone receptor is required for release of a putative co-repressor(s) necessary for transcriptional silencing. *Mol. Cell Biol.* 15: 176-186.
48. Cavailles, V., Dauvois, S., Danielian, P.S., and Parker, M.G., (1994). Interaction of proteins with transcriptionally active estrogen receptors. *Proc. Natl. Acad. Sci. USA* 91:10009-10013.
49. Halachmi, S., Marden, E., Martin, G., MacKay, I., Abbondanza, C., and Brown, M. (1994). Estrogen receptor-associated proteins: possible mediators of hormone-induced transcription. *Science* 264: 1455-1458.
50. Baniahmad, A., Leng, X., Burris, T.P., Tsai, S.Y., Tsai, M.J., and O'Malley, B.W. (1995). The tau4 activation domain of the thyroid hormone receptor is required for release of a putative corepressor(s) necessary for transcriptional silencing. *Mol. & Cell Biol.* 15: 76-86.
51. Hörlein, A.J., Näär, A.M., Heinzl, T., Torchia, J., Glass, B., Kurokawa, R., Ryan, A., Kamei, Y., Söderström, M., Glass, C.K., and Rosenfeld, M.G. (1995). Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. *Nature* 377: 397-404.
52. Chen, J.D., and Evans, R.M. (1995). A transcriptional co-repressor that interacts with nuclear hormone receptors. *Nature* 377: 454-457.
53. Kurokawa, R., Söderström, M., Hörlein, A.J., Halachmi, S., Brown, M., Rosenfeld, M.G. and Glass, C.K. (1995). Polarity-specific activities of retinoic acid receptors determined by a co-repressor. *Nature* 377: 451-454.
54. Oñate, S.A., Tsai, S.Y., Tsai, M.-J., and O'Malley, B.W. (1995). Sequence and characterization of a co-activator for the steroid hormone receptor superfamily. *Science* 270: 1354-1357.
55. Torchia, J., Rose, D.W., Inostroza, J., Kamei, Y., Westin, S., Glass, C.K., and M.G. Rosenfeld. p/CIP: A coactivator, p/CIP, binds CBP and mediates nuclear receptor function. *Nature* 387(6634): 677-684(1977).

56. Heinzel, T., R.M Lavinsky, T.-M. Mullen, M. Soderstrom, C.D. Laherty, J. Torchia, W.-M. Yang, G. Bard, S.D. Ngo, J.R. Davie, E. Seto, R. N. Eisenman, D. W. Rose, C. K. Glass and M.G. Rosenfeld. A complex containing N-CoR, mSin3, and histone deacetylases mediates transcription repression. *Nature* 387(6628): 43-48 (1997).
57. Kamei, Y. and Xu, L., Heinzel, T., Torchia, J., Kurokawa, R., Gloss, B., Lin, S-C., Heyman, R.A., Rose, D.W., Glass, C.K., and M.G. Rosenfeld. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. *Cell* 85(3): 403-414 (1996).
58. 60. Alland, L., Muhle, R., Hou Jr., H., Potes, J., Chin, L., Schreiber-Agus, N., and DePinho, R.A. (1997). Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression. *Nature* 387: 49-55.
59. Nagy, L., Kao, H.-Y., Chakravarti, D., Lin, R., Hassig, C., Ayer, D., Schreiber, S., and Evans, R.M. (1997). Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. *Cell* 89: 373-380.
60. Taunton, J., Hassig, C.A., and Schreiber, S.L. (1996). A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. *Science* 272: 408-411.
61. Yang, X.-Y., Ogryzko, V., Nishikawa, J., Howard, B. and Nakatani, Y. (1996). A p300/CBP-associated factor that completes with the adenoviral oncoprotein E1A. *Nature* 382: 319-324.
62. Ayer, D.E., Lawrence, Q.A., and Eisenman, R.N., (1995). Mad-Max transcriptional repression is mediated by ternary complex formation with mammalian homologs of yeast repressor Sin3. *Cell* 80: 767-76.
63. Schreiber-Agus, N., Chin, L., Torres, R., Guida, P., Skoultchi, A.I., and DePinho, R.A. (1995). An amino-terminal domain of Mx1 mediates anti-Myc oncogenic activity and interacts with a homolog of the yeast transcriptional repressor SIN3. *Cell* 80: 777-788.
64. Hassig, C., Fleischer, T., Billin, A., Schreiber, S., and Ayer, D. (1997). Histone deacetylase activity is required for full transcriptional repression by mSin3A. *Cell* 89: 341-348.
65. Kadosh, D., and Struhl, K. (1997). Repression by Ume6 involves recruitment of a complex containing Sin3 corepressor and Rpd3 histone deacetylase to target promoters. *Cell* 89: 365-372.
66. Laherty, C.D., Yang, W.-M., Sun, J.-M., Davie, J.R., Seto, E., and Eisenman, R.N. (1997). Histone deacetylase associated with the mSin3 corepressor mediate Mad transcriptional repression. *Cell* 89: 349-356.
67. Zhang, Y., Iratni, R., Erdjument-Bromage, H., Tempst, P., and Reinberg, D. (1997). Histone deacetylases and SAP18, a novel polypeptide, are components of a human Sin3 complex. *Cell* 89: 357-364.
68. Jackson, T.A., Richer, J., Bain, D., Takimoto, G., Tung, L., and Horwitz, K.B. (1997). The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. *Mol. Endo.* 11: 693-705.

69. Arias, J., Alberts, A.S., Brindle, P., Claret, F.X., Smeal, T., Karin, M., Feramisco, J., and Montminy, M. (1994). Activation of cAMP and mitogen responsive genes relies on a common nuclear ractor. *Nature* 370: 226-229.
70. Eckner, R., Ewen, M.E., Newsome, D., Gerdes, M., DeCaprio, J.A., Lawrence, J.B., and Livingston, D.M. (1994). Molecular cloning and analysis of the adenovirus E1A-associated 300-kD protein (p300) reveals a protein with properties of a transcriptional adaptor. *Genes & Dev.* 8: 869-884.
71. Kwok, R.P., Lundblad, J.R., Chrivia, J.C., Richards, J.P., Bächinger, Brennan, R., Roberts, S.G., Green, M.R., and Goodman, R.H. (1994). Nuclear protein CBP is a coactivator for the transcription factor CREB. *Nature* 270: 223-226.
72. Bannister, A.J., and Kouzarides, T. (1996). The CBP coactiator is a histone acetyltransferase. *Nature* 384: 641-643.
73. Ogryzko, V., Schlitz, R.L., Russanova, V., Howard, B., and Nakatani, Y., (1996). The transcriptional coactivators p300 and CBP are histone acetyltransferase. *Cell* 87: 953-959.
74. Katzenellenbogen, B.S., Montaono, M., LeGoff, P., Schodin, D., Kraus, W.L., Bhardwaj, B., and Fujimoto, N. (1995). Antiestrogens: Mechanisms and actions in target cells. *J. Steroid Biochem. Molec. Biol.* 53: 387-393.
75. Osborne, C.K., Elledge, R.M., and Fuqua, S.A. (1996). Estrogen receptors in breast cancer therapy. *Scientific America* 3: 32-41.
76. Osborne, C.K., and Fuqua, S.A. (1994). Mechanisms of tamoxifen resistance. *Breast Cancer Res. and Treat.* 32: 49-55.
77. Ali, S., Metzger, D., Bornert, J.-M., and Chambon, P. (1993). Modulation of transcriptional activation by ligand-dependent phosphorylation of the huan estrogen receptor A/B region. *EMBO J.* 12: 1153-1160.
78. Ignar-Trowbridge, D., Teng, C., Ross, K., Parker, M.G., Korach, K.S., and McLachlan, J.A., (1993). Peptide growth factos elicit estrogen receptor-dependent trascriptional activation of an estrogen response element. *Mol. Endo.* 7: 992-998.
79. Smith, C., Conneely, O., and O'Malley, B.W. (1993). Modulation of the ligand-independent activation of the human estrogen receptor by hormone and antihormone. *PNAS* 90: 6120-6124.
80. Fujimoto, N., and Katzenellenbogen, B.S. (1994). Alteration in the agonist/antagonist balance of antiestrogens by activation of protein kinase A signaling pathways in breast cancer cells: antiestrogen selectivity and promoter dependnce. *Mol. Endo.* 8: 296-304.
81. Ince, B.A., Montano, M., and Katzenellenbogen, B.S. (1994). Activation of transcriptionally inactive human estrogen receptors by cAMP and ligands including antiestrogens. *Mol. Endo.* 8: 1397-1406.
82. Bunone, G., Briand, P.-A., Miksicek, R., and Picard, D. (1996). Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathyway and direct phosphorylation. *EMBO J.* 9: 2174-2183.

83. El-Tanani, M.K.K., and Green, C.D. (1997). Two separate mechanisms for ligand-independent activation of the estrogen receptor. *Mol. Endo.* 11: 928-937.
84. Metzger, D., Ali, S., Bornert, J.-M. and Chambon, P. (1995). Characterization of the amino-terminal transcriptional activation function of the human estrogen receptor in animal and yeast cells. *Jour. Biol. Chem* 270: 9535-9542.
85. McInerney, E., Tsai, M.-J., O'Malley, B.W., and Katzenellenbogen, B.S. (1996). Analysis of estrogen receptor transcriptional enhancement by a nuclear hormone receptor coactivator. *PNAS* 93: 10069-10073.
86. Minton, J.P., Wisenbaugh, T., and Matthews, R.H. (1974). Elevated cAMP levels in human breast cancer tissue. *Jour. Natl. Cancer. Inst.* 53: 283.
87. Pietras, R., Arboleda, J., Reese, D., Wongvipat, N., Pegram, M., Ramos, L., Gorman, C., Parker, M.G., Sliwkowski, M., and Slamon, D.J. (1995). HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. *Oncogene* 10: 2435-2446.
88. Cho, H., and Katzenellenbogen, B.S. (1993). Synergistic activation of estrogen receptor-mediated transcription by estradiol and protein kinase activators. *Mol. Endo.* 7: 441-452.

9. APPENDIX

Figure 1: Model of regulation of specific corepressor complexes with nuclear receptors, and inhibition of the N-terminal activation function. Both ligands and external signaling pathways regulate the association of specific corepressor and coactivator complexes with nuclear receptors. At least one member of a receptor homo- or hetero-dimer binds strongly, in the absence of ligand, to either the N-CoR or SMRT-containing corepressor complex which localizes histone deacetylase activity to the promoter. This complex also simultaneously inhibits a constitutive N-terminal activation domain of the receptor. In the absence of the corepressor complex, and dependent at least in part on an N-terminal domain, receptors can exhibit constructive activity. The corepressor complex is dismissed by agonist ligands which simultaneously recruit an acetylase-containing coactivator complex that interacts with both the C-terminal AF-2 and the AF-1 activation domains in the receptor. Phosphorylation-dependent signaling pathways, initiated at the cell membrane, influence receptor activity by inhibiting the recruitment of the corepressor complex to steroid (ER/PR) and retinoid (RAR) receptors or, conversely, by stimulating its recruitment of peroxisome proliferator-activated receptor γ (PPAR γ).

